Cloete L. Diabetes mellitus: an overview of the types, symptoms, complications and management. Nurs Stand. 2022;37(1):61–6.

PubMed  Google Scholar 

Lovic D, Piperidou A, Zografou I, Grassos H, Pittaras A, Manolis A. The growing epidemic of diabetes mellitus. Curr Vasc Pharmacol. 2020;18(2):104–9.

CAS  PubMed  Google Scholar 

Demir S, Nawroth PP, Herzig S, Ekim UB. Emerging targets in type 2 diabetes and diabetic complications. Adv Sci (Weinh). 2021;8(18): e2100275.

PubMed  Google Scholar 

Kolaric V, Svircevic V, Bijuk R, Zupancic V. Chronic complications of diabetes and quality of life. Acta Clin Croat. 2022;61(3):520–7.

PubMed  PubMed Central  Google Scholar 

Ahmad K. Insulin sources and types: a review of insulin in terms of its mode on diabetes mellitus. J Tradit Chin Med. 2014;34(2):234–7.

PubMed  Google Scholar 

Bajaj HS, Bergenstal RM, Christoffersen A, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. Diabetes Care. 2021;44(7):1586–94.

CAS  PubMed  PubMed Central  Google Scholar 

Lingvay I, Buse JB, Franek E, et al. A randomized, open-label comparison of once-weekly insulin Icodec titration strategies versus once-daily insulin glargine U100. Diabetes Care. 2021;44(7):1595–603.

CAS  PubMed  PubMed Central  Google Scholar 

Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J Ophthalmol. 2021;69(11):2932–8.

PubMed  PubMed Central  Google Scholar 

Sapra A, Bhandari P. Diabetes. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Priyanka Bhandari declares no relevant financial relationships with ineligible companies.; 2023.

Sapra ABP. Diabetes. In: StatPearls [Internet] Treasure Island (FL): [Updated 2023 Jun 21]; StatPearls Publishing; 2023 Jan.

Newill VA. The Epidemiology of Diabetes Mellitus. Med Sci. 1963;14:30–9.

CAS  PubMed  Google Scholar 

Elafros MA, Andersen H, Bennett DL, et al. Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments. Lancet Neurol. 2022;21(10):922–36.

PubMed  PubMed Central  Google Scholar 

Tan TE, Wong TY. Diabetic retinopathy: looking forward to 2030. Front Endocrinol (Lausanne). 2022;13:1077669.

PubMed  Google Scholar 

Cheng A, Bailey TS, Mauricio D, Roussel R. Insulin glargine 300 U/mL and insulin degludec: a review of the current evidence comparing these two second-generation basal insulin analogues. Diabetes Metab Res Rev. 2020;36(7): e3329.

CAS  PubMed  Google Scholar 

Mehta R, Goldenberg R, Katselnik D, Kuritzky L. Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care. Ann Med. 2021;53(1):998–1009.

PubMed  Google Scholar 

Rumie Carmi HK, Dominguez-Menendez G, Araya M, Martinez-Aguayo A. New insulins for type 1 diabetes treatment. Andes Pediatr. 2023;94(3):278–85.

PubMed  Google Scholar 

Rosenstock J, Bajaj HS, Janez A, et al. Once-weekly insulin for type 2 diabetes without previous insulin treatment. N Engl J Med. 2020;383(22):2107–16.

CAS  PubMed  Google Scholar 

Rosenstock J, Bain SC, Gowda A, et al. Weekly Icodec versus daily glargine U100 in type 2 diabetes without previous insulin. N Engl J Med. 2023;389(4):297–308.

CAS  PubMed  Google Scholar 

Singh AK, Singh A, Singh R, Misra A. Once-weekly basal insulin icodec: looking ONWARDS from pharmacology to clinical trials. Diabetes Metab Syndr. 2022;16(9): 102615.

CAS  PubMed  Google Scholar 

Nishimura E, Pridal L, Glendorf T, et al. Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing. BMJ Open Diabetes Res Care. 2021;9(1): e002301.

PubMed  PubMed Central  Google Scholar 

Pratiwi C, Mokoagow MI, Made Kshanti IA, Soewondo P. The risk factors of inpatient hypoglycemia: A systematic review. Heliyon. 2020;6(5): e03913.

PubMed  PubMed Central  Google Scholar 

Ribeiro ESR, de Miranda Gauza M, Guisso MES, da Silva JON, Kohara SK. Once-weekly insulin icodec vs once-daily insulin glargine U100 for type 2 diabetes: a systematic review and meta-analysis of phase 2 randomized controlled trials. Arch Endocrinol Metab. 2023;67(5): e000614.

Google Scholar 

Russell-Jones D, Babazono T, Cailleteau R, et al. Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial. Lancet. 2023;402(10413):1636–47.

CAS  PubMed  Google Scholar 

Mathieu C, Asbjornsdottir B, Bajaj HS, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. Lancet. 2023;401(10392):1929–40.

CAS  PubMed  Google Scholar 

Bajaj HS, Aberle J, Davies M, et al. Once-weekly insulin Icodec with dosing guide app versus once-daily basal insulin analogues in insulin-naive type 2 diabetes (ONWARDS 5): a randomized trial. Ann Intern Med. 2023;176(11):1476–85.

PubMed  Google Scholar 

Philis-Tsimikas A, Asong M, Franek E, et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial. Lancet Diabetes Endocrinol. 2023;11(6):414–25.

CAS  PubMed  Google Scholar 

Yao L, Zhang Y, Zhao C, Zhao F, Bai S. The PRISMA 2020 statement: a system review of hospital preparedness for bioterrorism events. Int J Environ Res Public Health. 2022;19(23):16257.

PubMed  PubMed Central  Google Scholar 

Higgins JPT TJ CJ, Cumpston M, Li T, Page MJ, Welch VA, Editors. Cochrane Handbook for Systematic Reviews of Interventions. Cochrane; 2022; Cochrane Handbook for Systematic Reviews of Interventions.

RevMan. Review Manager Version. 5.4. Copenhagen: The Nordic Cochrane Centre, The Nordic Cochrane Centre TCC; 2020.

Google Scholar 

RevMan. Review Manager Version. 5.4. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2020.

Google Scholar 

Suurmond R, van Rhee H, Hak T. Introduction, comparison, and validation of Meta-Essentials: A free and simple tool for meta-analysis. Res Synth Methods. 2017;8(4):537–53.

PubMed  PubMed Central  Google Scholar 

Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.

PubMed  Google Scholar 

Migliavaca CB, Stein C, Colpani V, et al. Meta-analysis of prevalence: I(2) statistic and how to deal with heterogeneity. Res Synth Methods. 2022;13(3):363–7.

PubMed  Google Scholar 

Suurmond R, van Rhee H, Hak T. Introduction, comparison, and validation of meta-essentials: a free and simple tool for meta-analysis. Res Synth Methods. 2017;8:537–53.

PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;88:105906.

Google Scholar 

Vora J, Christensen T, Rana A, Bain SC. Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diabetes Ther. 2014;5(2):435–46.

CAS  PubMed  PubMed Central  Google Scholar 

Kerr D, Rajpura JR, Namvar T. Evaluating patient and provider preferences for a once-weekly basal insulin in adults with type 2 diabetes. Patient Prefer Adherence. 2024;18:411–24.

PubMed  PubMed Central  Google Scholar 

Abuelazm M, Ibrahim AA, Khlidj Y, et al. Once-weekly insulin icodec versus once-daily long-acting insulin for type ii diabetes: a meta-analysis of randomized controlled trials. J Endocr Soc. 2024;8(2):bvad177.

PubMed  Google Scholar 

Bajaj HS, Asbjornsdottir B, Bari TJ, Begtrup K, Vilsboll T, Rosenstock J. Once-weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: participant-level meta-analysis of the ONWARDS 1–5 trials. Diabetes Obes Metab. 2024;26(9):3810–20.

CAS  PubMed  Google Scholar 

Ahmed M, Shafiq A, Javaid H, et al. Clinical outcomes with once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-naive and previously insulin-treated individuals with type 2 diabetes: a meta-analysis of randomised controlled trials. Endocrinol Diabetes Metab. 2024;7(3): e00480.

CAS  PubMed  PubMed Central  Google Scholar 

Shetty S, Suvarna R. Efficacy and safety of once-weekly insulin icodec in type 2 diabetes: a meta-analysis of ONWARDS phase 3 randomized controlled trials. Diabetes Obes Metab. 2024;26(3):1069–81.

CAS  PubMed  Google Scholar 

Zuhair V, Obaid MA, Mustafa MS, et al. Evaluating the efficacy and safety of weekly Insulin Icodec vs. Daily Insulin Glargine in type 2 Diabetes Mellitus: a systematic review and meta-analysis. J Diabetes Metab Disord. 2024;23(1):1337–49.

CAS  PubMed  PubMed Central  Google Scholar 

Lisco G, De Tullio A, De Geronimo V, et al. Once-Weekly Insulin Icodec in Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Clinical Trials (ONWARDS Clinical Program). Biomedicines. 2024;12(8):1852.